Last reviewed · How we verify
Physician's choice treatments group
Physician's choice treatments group is a Small molecule drug developed by Yeon Hee Park. It is currently in Phase 2 development.
At a glance
| Generic name | Physician's choice treatments group |
|---|---|
| Sponsor | Yeon Hee Park |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast) (NA)
- Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer (PHASE2)
- Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer (PHASE2)
- ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer (PHASE2)
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Biliary Tract Cancers (PHASE2)
- A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma (PHASE2)
- Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer (PHASE2)
- Recognition of Circulating Tumor DNA in Soft Tissue Sarcoma
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Physician's choice treatments group CI brief — competitive landscape report
- Physician's choice treatments group updates RSS · CI watch RSS
- Yeon Hee Park portfolio CI
Frequently asked questions about Physician's choice treatments group
What is Physician's choice treatments group?
Physician's choice treatments group is a Small molecule drug developed by Yeon Hee Park.
Who makes Physician's choice treatments group?
Physician's choice treatments group is developed by Yeon Hee Park (see full Yeon Hee Park pipeline at /company/yeon-hee-park).
What development phase is Physician's choice treatments group in?
Physician's choice treatments group is in Phase 2.